Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04991480 · ClinicalTrials.gov registry record · Phase 1
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Artios Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 93
- Enrollment target
NCT04991480 is a Phase 1 study that has completed, run by Artios Pharma. The registered enrollment target is 93 participants.
The verdict
NCT04991480, a Phase 1 study, has completed, sponsored by Artios Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 93 participants
- Enrollment target
Study Summary
This clinical trial is evaluating a drug called ART4215 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART4215 that can be given safely to participants alone and in combination with talazoparib * Learn more about the side effects of ART4215 alone and in combination with talazoparib * Learn more about the effectiveness of ART4215 alone and in combination with talazoparib * Learn more about the effectiveness of ART4215 alone and in combination with niraparib
Interventions
- DRUG Talazoparib
- DRUG Niraparib
- DRUG ART4215
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2021-09-13 |
| Est. Completion | 2025-12-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04991480
The ClinicalTrials.gov registry entry for NCT04991480 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Artios Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Talazoparib is the first listed.
NCT04991480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04991480 about?
NCT04991480 is a clinical study titled "A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors". This clinical trial is evaluating a drug called ART4215 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART4215 that can be given safely to participants alone and in combination with talazoparib * Learn more about the sid...
What is the current status of trial NCT04991480?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2021-09-13. Estimated completion is 2025-12-24.
What interventions are being tested in trial NCT04991480?
The interventions under investigation include: Talazoparib (DRUG), Niraparib (DRUG), ART4215 (DRUG).
Who is sponsoring clinical trial NCT04991480?
This trial is sponsored by Artios Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.